Rani Therapeutics Posts $1.7 Million in Q3 Revenue, $0.04 GAAP Loss Per Share

John Kim

1 min read

Rani Therapeutics Posts $1.7 Million in Q3 Revenue, $0.04 GAAP Loss Per Share

Cash, cash equivalents and marketable securities totaled $45.3 million on Sept. 30, 2026, down from $53.4 million on June 30. Rani expects those funds to cover operations through at least the end of 2027.

By John Kim

Published Nov 10, 2026, 7:19 PM EST

Two clear glass reservoirs hold different levels of liquid / TokenPost.ai

Rani Therapeutics Holdings, Inc. posted $1.7 million in third-quarter revenue and a GAAP loss of $0.04 per share, while its cash, cash equivalents and marketable securities declined between June and September.

The combined balance was $45.3 million on Sept. 30, 2026, compared with $53.4 million on June 30.

Rani expects those funds to cover operations through at least the end of 2027 under its current operating plan.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.